Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

• Status: Withdrawn
• Trial end date: 2011-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Pfizer
• Treatments: Rifampin; Sitaxsentan

Criteria

Inclusion Criteria:

• Healthy male subjects and/or women of non-child bearing potential.

• Subjects between the ages of 21 and 55 years, inclusive.

• Signed informed consent.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.

• Has hepatic dysfunction.

• Has history of excessive alcohol and tobacco use.